Walleye Capital
TARS icon

Walleye Capital’s Tarsus Pharmaceuticals TARS Stock Holding History

Walleye Capital’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$749K Sell
11,906
-3,278
-22% -$209K ﹤0.01% 2373
2026
Q1 		$1.07M Sell
15,184
-25,089
-62% -$1.75M ﹤0.01% 2019
2025
Q4 		$3.3M Buy
40,273
+30,790
+325% +$2.3M 0.01% 1464
2025
Q3 		$564K Sell
9,483
-435
-4% -$21.4K ﹤0.01% 2515
2025
Q2 		$402K Buy
+9,918
New +$446K ﹤0.01% 2818
2024
Q3 		– Sell
-75,588
Closed -$2.05M – 5852
2024
Q2 		$2.05M Sell
75,588
-196,910
-72% -$6.62M ﹤0.01% 2072
2024
Q1 		$9.91M Buy
+272,498
New +$8.01M 0.02% 833

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Walleye Capital's TARS Position: Q2 2026 in Review

Walleye Capital reduced its Tarsus Pharmaceuticals (TARS) stake by 22% in Q2 2026, selling an estimated $209K and leaving 11,906 shares worth $749K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

Walleye Capital first reported a position in TARS in Q1 2024 and has held it in 7 quarters since. The position peaked at $9.91M in Q1 2024. 256 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Walleye Capital held 11,906 shares of Tarsus Pharmaceuticals worth $749K as of Q2 2026.
  • Walleye Capital sold 3,278 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $209K.
  • Tarsus Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #2373 holding.
  • Walleye Capital first reported a position in Tarsus Pharmaceuticals in Q1 2024 and has held it in 7 quarters since.
  • Walleye Capital's Tarsus Pharmaceuticals position peaked at $9.91M in Q1 2024.
  • 256 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.